FFA
SYRE icon

Farther Finance Advisors’s Spyre Therapeutics SYRE Stock Holding History

Farther Finance Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$98.8K Sell
1,110
-19
-2% -$1.83K ﹤0.01% 2871
2026
Q2 		$100K Buy
1,129
+1,055
+1,426% +$77K ﹤0.01% 2702
2026
Q1 		$3.62K Buy
74
+37
+100% +$1.4K ﹤0.01% 4658
2025
Q4 		$1.21K Buy
37
+27
+270% +$706 ﹤0.01% 4864
2025
Q3 		$168 Buy
+10
New +$163 ﹤0.01% 4756

Other funds holding SYRE

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's SYRE Position: Q3 2026 in Review

Farther Finance Advisors reduced its Spyre Therapeutics (SYRE) stake by 1.7% in Q3 2026, selling an estimated $1.83K and leaving 1,110 shares worth $98.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

Farther Finance Advisors first reported a position in SYRE in Q3 2025 and has held it in 5 quarters since. The position peaked at $100K in Q2 2026. 2 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Farther Finance Advisors held 1,110 shares of Spyre Therapeutics worth $98.8K as of Q3 2026.
  • Farther Finance Advisors sold 19 Spyre Therapeutics shares in Q3 2026, an estimated $1.83K.
  • Spyre Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #2871 holding.
  • Farther Finance Advisors first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Farther Finance Advisors's Spyre Therapeutics position peaked at $100K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.